Olema Pharmaceuticals Stock Falls as Pivotal Breast Cancer Data Pushed Into 2027 - Olema Pharmaceuticals

Olema Pharmaceuticals shares fall after completing OPERA-01 Phase 3 enrollment, with top-line data now expected in Q1 2027.

Raccontata dabenzinga.com